FDA Approves Lebrikizumab Every-8-Week Maintenance Dosing for Moderate-to-Severe Atopic Dermatitis

FDA approved an every-8-week (Q8W) maintenance dosing regimen for Eli Lilly and Company’s (Lilly) lebrikizumab-lbkz (Ebglyss), the company announced on June 9, 2026. The new dosing regimen is intended for adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical prescription therapies.¹

The approval expands on the existing every-4-week (Q4W) maintenance regimen, which makes lebrikizumab the only approved biologic for AD that offers as few as 6 maintenance injections per year without mandatory concomitant topical therapy from treatment initiation, according to Lilly. The approval is based on longitudinal exposure-response modeling and is supported by extension data from a phase 3 long-term trial (ADjoin).

"The option to extend [Ebglyss]maintenance dosing to every eight weeks represents an important moment for patients living with moderate-to-severe atopic dermatitis," said Peter Lio, MD, author of the ADjoin study and clinical assistant professor of dermatology and pediatrics at Northwestern University, in a company press release.¹ "This new dosing regimen without mandatory topicals gives patients a new option to manage their condition based on individual needs."

What is the approved dosing regimen, and what evidence supports the Q8W maintenance interval?

The approved regimen initiates with lebrikizumab 500 mg (2 x 250 mg injections) at weeks 0 and 2, followed by 250 mg every 2 weeks through week 16 or until adequate clinical response is achieved. Maintenance dosing is then 250 mg Q4W or 250 mg Q8W. The Q8W approval was supported by longitudinal exposure-response modeling data and by the Q8W ADjoin extension (NCT04392154), a 32-week open-label study evaluating Q8W and Q4W dosing in adult and adolescent patients who had completed the 100-week ADjoin long-term study.

The ADjoin study enrolled completers from the ADvocate 1 and 2, ADore, and ADopt-VA phase 3 trials. Patients received 250 mg Q8W or Q4W regardless of their prior dosing interval or response status at extension baseline. No new safety signals were identified over 32 weeks, and no patients discontinued due to adverse events during the extension period.¹

What is the clinical context and disease burden of moderate-to-severe AD?

AD is a chronic, relapsing type 2 inflammatory skin disease affecting approximately 15% to 20% of children and 1% to 3% of adults globally, with moderate-to-severe disease associated with significant impairment in sleep, quality of life, psychological well-being, and daily functioning.² The pathophysiology is driven by dysregulation of the type 2 immune axis, with interleukin-4 (IL-4) and IL-13 as central mediators of skin barrier disruption, pruritus, and chronic inflammation.³

Treatment burden, including frequent clinic visits, concomitant topical regimens, and monitoring requirements, contributes to suboptimal adherence and patient dissatisfaction with existing therapies.² Biologic therapies targeting the IL-4/IL-13 pathway have transformed the management of moderate-to-severe disease, but dosing frequency and topical requirements have remained areas of unmet need from the patient perspective.

What is lebrikizumab's mechanism of action, and how does it differ from other approved IL-13–targeting biologics?

Lebrikizumab is an immunoglobulin G4 monoclonal antibody (mAb) that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate. It binds at a site that overlaps with the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer and prevents receptor complex formation and downstream IL-13 signaling.³ This mechanism is distinct from dupilumab, which blocks the shared IL-4Rα receptor subunit, inhibiting both IL-4 and IL-13 signaling simultaneously.^4-5

Tralokinumab is another approved anti–IL-13 mAb that neutralizes IL-13, but this mAb binds at a different epitope than lebrikizumab.⁴ The clinical significance of these mechanistic distinctions in terms of comparative efficacy or safety has not been established in head-to-head trials. Lebrikizumab was first approved in the European Union in 2023 and received US, Japanese, and Canadian approvals in 2024.¹

How can the Q8W approval be interpreted in the context of the existing AD treatment landscape?

The extended dosing interval is an important outcome because it enables convenience, particularly for a chronic disease requiring indefinite maintenance therapy. It may therefore support adherence and reduce treatment burden.² However, the Q8W approval rests on exposure-response modeling and extension trial data rather than a prospectively powered, randomized comparison of Q4W versus Q8W efficacy.

The ADjoin Q8W extension was open-label and enrolled patients who had already demonstrated sufficient disease control to complete the 100-week ADjoin study. This patient group may not reflect outcomes in a broader real-world population initiating or switching maintenance schedules.⁴ Whether Q8W dosing maintains equivalent long-term disease control to Q4W across the full spectrum of disease severity, including patients with more refractory disease, will require longer-term post-approval data.

What limitations apply to this approval, and what further evidence is anticipated?

Efficacy data specifically comparing Q8W to Q4W outcomes in a randomized, controlled design are not available at this time, and FDA’s approval relied in part on pharmacokinetic and exposure-response modeling. The extension study population represented a selected group of long-term responders, which limits generalizability to patients earlier in the treatment course or those who have experienced incomplete responses.

Lilly holds US and ex-European global rights to lebrikizumab, while Almirall holds European commercialization rights. The Q8W label update has not yet been reviewed by European or other regulatory authorities. Post-marketing data on real-world outcomes under the Q8W regimen, including relapse rates and dose interval adjustments, will be important for guiding shared clinical decision-making.

References

1. Eli Lilly and Company. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. Published June 9, 2026. Accessed June 10, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglyssr-lebrikizumab-lbkz-one-maintenance
2. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z
3. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-1482. doi:10.1111/all.12049
4. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080-1091. doi:10.1056/NEJMoa2206714
5. Simpson EL, Bieber T, Guttman-Yassky E, et al.. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020